Omalizumab Therapeutic Cheat Sheet
OmalizumabChronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …
Omalizumab
Patient Buzz Series: Acne Scar Treatments
acne scarsHow to treat acne scars is a popular topic in the consumer press this month. Online articles discussed the benefits and limitations of both chemical peels and scar creams. What advice is your acne patients reading about fading their acne scars and post-inflammatory hyperpigmentation? Find out by reviewing this list of articles about hot dermatology topics in the consumer press: Allur …
acne scars
Skincare Mondays | Improving Quality of Life for Eczema Patients
eczemaAtopic dermatitis (AD) is a chronic skin condition characterized by pruritus, inflammation, and acute flare-ups of eczematous lesions over dry skin.1 The wide range of clinical manifestations, the visible nature of the disease, and the intense itching significantly affects patients’ quality of life.2  Up to 80% of children with AD experience sleep disturbances.3 Sixty-seven percent of children …
eczema
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
psoriasisPsoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of targeted biologic agents offers safe, effective options for children with moderate-to-severe skin and nail disease. A few are now Food and Drug Administration (FDA)-approved for children. INTRODUCTIO …
psoriasis
Translating Psoriasis Guidelines into Practice
psoriasis guidelinesBefore we dive into our discussion, let’s outline the Guideline-Based Approach to Treatment Selection. The International Psoriasis Council has divided psoriasis treatment classification into 2 groups: Patients who are a candidate for topical therapy, or Patients who are a candidate for systemic therapy Candidates for systemic therapy must meet at least 1 of the following …
psoriasis guidelines